Dexylin Eye (ANTIBACTERIALS)

Quick links

Choose a section

Quick links to important sections

Advertisements

Dexylin Eye (ANTIBACTERIALS)

Advertisements
Advertisements

Treatment option: Coma, Hepatic Coma, Encephalopathy

Advertisements

Overview of Dexylin Eye (ANTIBACTERIALS)

Property Description
Active ingredient Neomycin
Form Sterile ophthalmic solution (Eye drops)
Pharmacological class Aminoglycoside Antibiotic
General purpose Anti-infective agent for ocular infections
Origin Synthetic compound

What Type of Medicine is Dexylin Eye?

Dexylin Eye is an ophthalmic preparation classified as an ANTIBACTERIALS agent, specifically belonging to the aminoglycoside antibiotic pharmacological class. This classification signifies that the drug is built to fight bacterial growth effectively. The medication functions as a prescription-only medicine (POM) intended to address ocular infection caused by susceptible bacteria. As a highly targeted treatment, it provides a crucial local action by focusing its therapeutic effect directly on the eye's surface, a methodology recognized for enhancing concentration at the site of infection. This feature makes it particularly suitable for treating typical surface infections of the eye.

Composition and Form: What is Neomycin and the Drug's Delivery?

The core component defining Dexylin Eye is its active ingredient, the generic compound Neomycin (typically present as Neomycin sulfate). Neomycin is a synthetic compound derived from bacterial sources and is formulated as a single-ingredient product. The medicine is prepared as a sterile ophthalmic solution, commonly known as eye drops, which consists of the active ingredient dissolved in a safe, aqueous vehicle suitable for direct eye application. Neomycin is used in the treatment of surface infections, and the active component is widely recognized for its ability to clear external microbial presence.

General Benefit: How Does This Antibiotic Help the Eye?

The general therapeutic purpose of Dexylin Eye is to eliminate the bacteria responsible for an infection, leading to the resolution of the infectious condition. The Neomycin compound achieves this through a potent bactericidal action by interfering with the bacteria’s vital internal processes, acting as a protein synthesis inhibitor. This mechanism ensures the medicine directly addresses the cause of the bacterial presence, supporting the healing of the eye's surface. The use of this drug is a typical, neutral scenario for patients experiencing mild to moderate bacterial eye infections.

Advertisements

What side effects are possible with Dexylin Eye (ANTIBACTERIALS)?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics for ophthalmic preparations containing Neomycin, the active ingredient in Dexylin Eye, as classified by regulatory authorities.


Adverse Reaction Profile

Adverse reactions are primarily associated with the immune system and local ocular and skin disorders. The most frequently reported reactions are localized allergic sensitizations and hypersensitivity reactions to the antibiotic component, although official incidence figures are generally not known (Not Known) from regulatory post-marketing data.

Reactions most often reported include local ocular discomfort, eye irritation, itching (pruritus), swelling (edema) of the eyelid or conjunctiva, and conjunctival redness (erythema). A failure of the original condition to heal may also be a manifestation of sensitization.

Rarely reported serious adverse reactions include severe hypersensitivity events such as anaphylaxis or bullous reactions.


Safety Considerations and Limitations

Duration-Related Risk: The regulatory profile notes that prolonged use of the anti-infective component may result in the overgrowth of non-susceptible organisms, including fungi (superinfection).

Systemic Risk Note: Although absorption is typically low after ophthalmic use, the neomycin class is associated with the potential for serious systemic effects, including neurotoxicity, ototoxicity (affecting hearing and balance), and nephrotoxicity (affecting the kidneys). This necessitates caution regarding concomitant or sequential use with other drugs possessing similar toxic effects.

Use Restrictions: This medication is strictly NOT FOR INJECTION (intraocular or periocular use). Additionally, safety and effectiveness in pediatric patients have not been established.

These official safety statements define the medicine’s risk profile, primarily focusing on local immune responses and acknowledging potential class-specific systemic toxicity under specific conditions, as documented in government regulatory labeling.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for this ophthalmic solution addresses two distinct scenarios: topical overuse and the far greater risk of systemic exposure.

Documented Manifestations and Immediate Actions Overuse applied directly to the eye may result in local ocular signs that mirror known adverse reactions, such as punctuate keratitis, erythema (redness), and lid oedema (swelling). Regulatory documentation advises that in such cases, the excess solution may be flushed from the affected eye(s) using lukewarm water.

When Urgent Medical Help is Required The primary severe risk is associated with the active ingredient's systemic toxicity if the solution is accidentally swallowed or highly absorbed. Regulatory instructions mandate that you contact a Poison Control Center or emergency room at once if this medication is swallowed. Immediate emergency services must be called if the individual shows signs of severe distress, including collapse, a seizure, trouble breathing, or if they cannot be awakened.

Potential Severe Outcomes and Supportive Management Systemic exposure carries the risk of serious toxic effects, notably ototoxicity (hearing damage) and nephrotoxicity (kidney damage). Life-threatening outcomes such as neuromuscular blockage and respiratory paralysis are documented risks associated with this drug class. Management is generally symptomatic and supportive. Special consideration is given to pediatric and geriatric populations, which may be more sensitive to the drug's systemic toxic effects.

Advertisements

Therapeutic Uses of Dexylin Eye (ANTIBACTERIALS)

What Dexylin Eye (ANTIBACTERIALS) treats: main uses and benefits

This medication is commonly used across conditions presenting with acute episodes that involve an active bacterial presence affecting the external parts of the eye. It is applied in clinical settings marked by heightened symptoms to assist in managing the microbial load, thus contributing to the management of the condition.

This medication is considered relevant for conditions presenting with localized discomfort, such as bacterial conjunctivitis (pink eye), bacterial blepharitis (eyelid inflammation), and superficial forms of keratitis. It helps address symptom clusters that may become intense or disruptive, such as pronounced redness, ocular irritation, eyelid swelling, and purulent discharge. This supportive action may help ease the overall symptom burden.

Applied during phases of increased distress, this treatment provides supportive benefit by addressing the symptoms associated with the acute bacterial presence. It offers short-term symptomatic assistance, which may assist with maintaining functional stability, allowing patients to cope more steadily with difficult episodes.


Quick Fact: Relief for Ocular Discomfort

This ophthalmic preparation assists with maintaining functional stability and contributes to improved comfort by addressing the symptomatic discomfort associated with the inflammation, which commonly interferes with routine activities.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Population Eligibility and Non-Eligibility

The eligibility for using Dexylin Eye is determined by specific patient factors and the type of ocular infection being treated, as defined by official regulatory documents.

Absolute Contraindications

Use of this medicine is formally prohibited (contraindicated) for individuals with a known or suspected hypersensitivity or allergy to the active ingredient, Neomycin, or any other component of the drops. Eligibility is also strictly prohibited for specific types of ocular infections, including those caused by viral diseases (such as Epithelial Herpes Simplex Keratitis), fungal diseases, or mycobacterial infections of the eye, as the antibiotic is ineffective against these pathogens.

Age-Related and Restricted Use

The medicine is officially permitted for use in adults, older adults, and children 2 years of age and older. However, safety and effectiveness have formally not been established in pediatric patients younger than 2 years of age. For pregnant and lactating individuals, use is restricted and generally not recommended unless a healthcare provider determines that the potential benefit justifies the potential risk. An additional restriction applies to contact lens wearers, who must remove soft lenses prior to administration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The potential for significant interactions with other systemically administered medicines is generally considered low due to the minimal systemic absorption of the ophthalmic suspension. However, caution is advised regarding certain classes of products, as the corticosteroid component, dexamethasone, has known interaction mechanisms.

Product Category Interaction Note (Mechanism)
Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration may increase the risk of corneal healing problems or delayed healing of eye wounds.
CYP3A4 Inhibitors (e.g., ritonavir, cobicistat) These agents may increase the systemic levels of the dexamethasone component, potentially leading to a higher risk of systemic corticosteroid side effects, such as adrenal suppression.

It is essential to avoid using other ophthalmic products, including other eye drops or ointments, without specific medical guidance. If multiple ophthalmic products are prescribed, they should be administered with a sufficient time interval (e.g., at least five to ten minutes) to prevent drug washout.

Use of this combination product is generally contraindicated in the presence of most viral diseases of the cornea and conjunctiva, including herpes simplex keratitis, as well as in ocular fungal or mycobacterial infections, as the corticosteroid component may suppress host resistance and worsen these conditions.

Advertisements

Mechanism of Action

Molecular Blockade of Bacterial Protein Synthesis

This mechanism involves the active ingredient, Neomycin, binding irreversibly to the 30S ribosomal subunit inside susceptible bacteria. This targeted action interferes with the cell's genetic decoding process, resulting in the production of non-functional, faulty structural and enzymatic proteins essential for structure and replication.

Cascade Leading to Bactericidal Action

The introduction of non-functional proteins destabilizes the bacterial structure, notably compromising the outer cell membrane integrity. This breakdown accelerates the drug's uptake and causes the leakage of vital cellular contents, ensuring a rapid, concentration-dependent, bactericidal action against susceptible organisms.

Mechanistic Constraints and Limitations

The drug's mechanism relies on an oxygen-dependent transport process to enter the bacterial cell, rendering it significantly less effective against organisms in low-oxygen (anaerobic) environments. Furthermore, the action can be entirely bypassed by certain bacteria that possess enzymes capable of chemically inactivating Neomycin before it reaches its ribosomal target.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Dexylin Eye Suspension

Route and Preparation

This medication is strictly for ocular use (topical application to the eye). The bottle must be shaken well before use to ensure the suspension is uniform. To prevent contamination, do not allow the dropper tip to touch the eye, eyelids, or any other surface. If you notice the tamper-evident snap collar is loose after removing the cap, remove the collar before instillation.

Dosing and Frequency

The standard dosage is one or two drops instilled into the conjunctival sac(s) every four to six hours while the patient is awake. For severe conditions, the dosage may be temporarily increased to one or two drops every two (2) hours during the initial 24 to 48 hours. The frequency must be decreased gradually as warranted by clinical improvement. It is essential not to discontinue therapy prematurely, even if symptoms improve.

Procedural Steps

To apply the drops, tilt the head back, gently pull down the lower eyelid to form a small pouch, and instill the prescribed number of drops into this sac. Close the eye gently for one to two minutes afterward. Nasolacrimal occlusion (applying gentle pressure to the inner corner of the eye near the nose) is recommended immediately after instillation to reduce the systemic absorption of the product. If you are using other topical ophthalmic products, a minimum interval of five minutes should be allowed between applications, with eye ointments administered last.

Special Use Rules

Dexylin Eye suspension may be used in the pediatric population aged 2 years and older at the same dosage as adults; safety and effectiveness have not been established for children younger than 2 years of age. Soft contact lenses must not be worn during the use of this product. If a dose is missed, administer it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule; do not use a double dose.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Dexylin Eye (ANTIBACTERIALS)

Evidence for use in Acute Bacterial Conjunctivitis

The research base for this medicine includes studies examining acute bacterial conjunctivitis, a condition characterized by periods of heightened symptoms like redness and discharge. The available evidence includes systematic reviews and meta-analyses synthesizing findings from short-term Randomized Controlled Trials (RCTs).

These trials were used in research exploring how symptoms change, specifically measuring Clinical Remission (tracking the resolution of visible signs) and Microbiological Remission (monitoring the disappearance of the bacterial pathogen). Findings describe patterns observed in the studies related to measurements of clinical clearance or bacterial eradication. This evidence contributes to understanding symptom patterns in acute, irritative states.

Evidence for use in Superficial Bacterial Keratitis

The active ingredient in Dexylin Eye was also studied for superficial bacterial keratitis, a condition marked by functional limitations. Research has explored this use through a mix of smaller prospective trials and observational studies, which evaluated the preparation within research scenarios involving temporary physiological imbalance.

In these settings, studies examined outcomes related to healing. Researchers monitored outcomes such as the time required to achieve corneal re-epithelialisation (closure of the surface defect) and the time to clinical presumed cure. Findings described group patterns related to the measured healing outcomes.

Focus of Long-Term Studies and Follow-up Research

Research has primarily focused on the acute phase of infection, meaning follow-up durations were limited in most key trials. Research does not characterize long-term outcomes or the durability of the reported effects. There is limited information for long-term outcomes and the rate of recurrence following the conclusion of the short-term treatment.

Study Design and Research Limitations

Evidence remains limited for certain patient subgroups, such as older adults with comorbidities and specific pediatric populations. The primary limitation of the research base is that most pivotal studies evaluated Neomycin as a component of a combination ophthalmic product, making the specific contribution of the single-ingredient solution difficult to characterize. Evidence quality varies across studies, and data are still emerging in several areas.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dexylin Eye (ANTIBACTERIALS) (FAQ)


Q: Can Dexylin Eye be used for conjunctivitis (pink eye)?

Official drug information indicates that the active ingredients in this medicine have been studied and are used in the management of conditions such as acute bacterial conjunctivitis (often known as pink eye). These studies focus on its role in addressing the visible signs and bacterial presence associated with this type of infection.


Q: Can I use Dexylin Eye if I am pregnant or breastfeeding? (asking for general safety classification)

Use during pregnancy is officially documented as restricted and is typically not recommended unless a healthcare provider determines the potential benefits may justify the potential risks. Similarly, caution is advised when using this product while breastfeeding, as many medicines may be excreted into human milk.


Q: Does Dexylin Eye expire quickly once the bottle is opened?

Official storage instructions require that the remaining eye solution be discarded 28 days after the bottle is first opened. This rule is documented in official storage instructions for maintaining product sterility, regardless of the remaining volume.


Q: Is there a maximum duration of time that Dexylin Eye is generally recommended to be used?

Guidance on the antibacterial component suggests that treatment duration should generally be limited to 10 days. Using the medication for a longer period is associated with a documented risk of adverse events and may be linked to the potential overgrowth of non-susceptible organisms.


Q: Is it possible to develop resistance to Dexylin Eye over time?

Regulatory-linked information indicates that not fully eradicating the bacteria may increase the possibility that the infection will not be completely resolved, potentially leading to the development of bacterial resistance to the antibiotic over time.


Q: Can I use other types of eye drops (like artificial tears) while using Dexylin Eye?

Official administration guidelines state that if you are using other topical ophthalmic products, a minimum interval of five minutes should be allowed between applications. If an eye ointment is also prescribed, it is generally administered last.


Q: How quickly should I expect to see an improvement after starting Dexylin Eye?

Official patient information indicates that improvement in the eye condition is often observed during the first few days of treatment. If improvement is not observed or if symptoms worsen, official guidance recommends consultation with a healthcare provider.


Q: Is it normal to feel a temporary stinging sensation after using Dexylin Eye?

Regulatory-linked information frequently lists mild eye irritation and localized burning or stinging as adverse reactions that have been reported by patients. This temporary discomfort is considered a common effect of topical ophthalmic products.


Q: What should I do if the symptoms don't improve after a few days of using Dexylin Eye?

Official regulatory guidance requires consultation with a healthcare provider if symptoms do not improve within the first few days of treatment or if the condition appears to worsen.


Q: What happens if Dexylin Eye is used when there is no bacterial infection?

This product is formulated to treat bacterial infections. Using it when a bacterial infection is not present, or for infections caused by viruses or fungi, may carry a risk of encouraging the overgrowth of non-susceptible organisms.


Q: Can Dexylin Eye affect my vision temporarily?

Regulatory-linked safety information states that the drug may temporarily cause blurred vision or other mild visual changes immediately after use. For this reason, official warnings recommend exercising caution when operating machinery or driving until vision is clear.


Q: Is Dexylin Eye available over the counter in some countries?

Dexylin Eye is designated as a prescription-only medicine (POM) in many jurisdictions. It requires a valid prescription from an authorized health professional for its use and distribution.


Q: What is the official safety rating or classification of Dexylin Eye?

The drug’s safety profile is defined by official warnings regarding the potential for local hypersensitivity (allergic) reactions. Other key safety considerations include the documented risk of bacteria developing resistance with prolonged use, which influences the typical duration of treatment.


Q: Can Dexylin Eye cause an allergic reaction?

Yes, official safety information lists the potential for developing an allergic sensitization or a hypersensitivity reaction to the active ingredients. Regulatory documents include warnings about the symptoms associated with a severe allergic event.


Q: Do official documents mention the possibility of the infection returning after stopping Dexylin Eye?

Official patient guidance describes that stopping the medicine before the full prescribed regimen is finished, even if symptoms improve, is associated with the risk of the infection returning.


Q: Are there different strengths or formulations of Dexylin Eye?

The single-ingredient product, Dexylin Eye, is officially defined as a sterile ophthalmic solution (eye drops). The active ingredient may be found in other strengths or formulations, such as thicker ointments, under different product names.


Q: What is the difference between an eye drop and an eye ointment formulation of an antibacterial?

The primary distinctions lie in their consistency and application. Drops are liquid and generally require more frequent application. Ointments are thicker, which allows them to remain on the eye's surface for a longer period, often resulting in less frequent required dosing.


Q: Is it safe to drive or operate machinery after using Dexylin Eye?

Because this medication may cause temporary blurred vision after administration, official safety warnings indicate that individuals should wait until their vision is completely clear before engaging in tasks such as driving or operating machinery.


Q: Do any foods or supplements interact with Dexylin Eye?

Due to the nature of eye drops, which results in minimal medicine absorption into the body, the risk of interaction with common foods or dietary supplements is generally considered to be low.


Q: Can I use Dexylin Eye for an ear infection or a skin infection? (asking about common user error)

This product is strictly indicated for ophthalmic use—meaning for use in the eye only. The official documentation for the active ingredient explicitly cautions against using the eye formulation for other uses, such as in the ear or on the skin.


Q: Is it normal for the fluid in the bottle to look slightly colored?

The product is officially described as a sterile ophthalmic solution or suspension. Descriptions for similar formulations containing this ingredient often note that the liquid appearance can range from clear and colorless to a light, yellowish hue.


Q: Why do official materials recommend not sharing the bottle of Dexylin Eye?

Official product information advises strongly against sharing the medication with another person, even if they have similar symptoms. This precaution is meant to prevent the potential spread of infection and contamination between individuals.


Q: Why might a doctor prescribe a different antibacterial eye drop instead of Dexylin Eye?

The active ingredient in this medication is effective only against a specified list of susceptible bacteria. A different antibacterial may be prescribed if the infection is confirmed to be caused by a type of bacteria, such as Serratia marcescens, against which this product is not considered adequately effective.


Q: What is the typical time frame for the onset of action of Dexylin Eye?

While the exact onset is not formally quantified in regulatory labeling, patient information suggests that improvement in symptoms is often observed within the first few days of treatment.


Q: Is Dexylin Eye only effective against certain types of bacteria?

Yes, official microbiology information states that the drug is effective only against specific susceptible microorganisms. It is noted that the medicine may not provide adequate coverage against certain others, which guides its appropriate use.

Advertisements

How should Dexylin Eye (ANTIBACTERIALS) be stored and disposed of?

Storage Conditions

The ophthalmic solution must be stored at controlled room temperature, typically maintained between 20 C to 25 C (68 F to 77 F). The official labeling strictly requires that the product be kept from freezing and stored away from excessive heat, moisture, and direct light.

To ensure the sterility of the multi-dose container, it must be kept tightly closed when not in use. A crucial stability requirement is to discard the remaining solution 28 days after the bottle is first opened, regardless of how much medicine is left. The product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Dexylin Eye must follow local, regional, national, and international regulations for medicinal waste. It is prohibited to keep outdated medicine. If a local drug take-back program is unavailable, non-flushable medicines may be mixed with an undesirable substance (such as dirt) in a sealed container and placed in the household trash, following the precautionary steps outlined by government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexylin Eye (ANTIBACTERIALS) found in:

A-Z Index: